ASH 2024: Focus on Lymphoma
Review key research and clinical insights on lymphoma care presented at the 66th ASH Annual Meeting and Exposition.
Advertisement
Advertisement
Fludararabine lymphodepletion is more effective than bendamustine lymphodepletion, but more follow-up is needed to confirm.
Updated results from the phase 3 ECHO trial were presented at ASH 2024.
A new study aimed to confirm the possible synergy between loncastuximab and rituximab.
A phase 2 study presented at ASH 2024 hint at a chemo-free option for elderly patients with MCL
Researchers at the 2024 American Society of Hematology Annual Meeting said follicular lymphoma is biologically diverse.
The evolving role of HSCT aAHSCT, and allo-HSCT requires further clarification amid new treatment advances in WM.
Future research must focus on developing more effective therapies to address the unmet needs of this high-risk MCL.
Treatment choice significantly influences outcomes in patients with mantle cell lymphoma.
The efficacy of HSCT for FL and provides a benchmark for testing emerging therapies like CAR-T and bispecific antibodies.
Researchers generated Patient-Derived Lymphoma Tumoroids to replicate the FL tumor microenvironment.
Researchers at ASH 2024 explained that adolescents and young adults with non-Hodgkin lymphoma face fertility challenges.
Future studies should explore combining allo-HSCT with novel therapies to enhance outcomes further.
The functional and structural relevance of IGHV1-204 remains unclear for patients with splenic marginal zone lymphoma.
A retrospective analysis observed 3,897 patients with lymphoma enrolled in 32 cooperative group trials between 2005 and 2020.
Marginal zone lymphoma lacks extensive research on its real-world treatment patterns and economic impact.
Patients with follicular lymphoma and early progression are a distinctly vulnerable population who need further study.
The approach demonstrated safety and produced response in B-ALL, DLBCL, follicular lymphoma, and MCL.
Encouraging initial study findings in mice will inform the design of a BHB supplementation trial in human patients.
A large, multicenter retrospective study found favorable efficacy and toxicity with this approach.
Odronextamab achieved high ORR and CR rates in patients with relapsed or refractory third line FL
Acalabrutinib, umbralisib, and ublituximab treatment is effective in patients with de novo MCL, with a 100% CR rate.
Fixed-duration epcoritamab with rituximab plus lenalidomide drives deep and durable responses in follicular lymphoma.
Upfront treatment with fixed-duration subcutaneous mosunetuzumab demonstrated a high complete response rate in FL and MZL.
A study stresses psychological support as an essential component of comprehensive cancer care.
Good local control over five years using a very low dose approach was possible for potentially curable patients.
A phase I/II first-in-human study evaluates a new bivalent small molecule in relapsed or refractory FL and MZL.
Study investigated if high Vulnerable Elders Survey scores were associated with changes in quality of life across age groups.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.